我院2009-2010年抗骨质疏松症药应用分析  

Analysis of the Application of Anti-osteoporosis Agents in Our Hospital during 2009-2010

作　　者：陈志刚[1,2] 崔岩峥[1,2] 杨丽娟[1,2] 甄健存[1,2] 

机构地区：[1]北京积水潭医院 [2]北京大学第四临床医学院,北京100035

出　　处：《中国药房》2012年第6期520-522,共3页China Pharmacy

摘　　要：目的:了解我院抗骨质疏松症(OP)药的应用现状。方法:采用用药频度、日均费用等药物经济学参数,对我院2009-2010年抗OP药处方进行统计和分析。结果:我院抗OP药以钙剂和维生素D为基础,降钙素类药为销售金额最大的品种,双膦酸盐和选择性雌激素受体调节剂为常规治疗药物;单一药物治疗约占总处方数的76%。结论:我院抗OP药处方用药结构稳定,总体上符合临床治疗指南,但应进一步加强患者依从性研究。OBJECTIVE： To investigate the application of anti-osteoporosis （OP） agents in our hospital. METHODS： Pharma- coeconomic parameters such as DDDs and DDC were employed to statistically analyze anti-osteoporosis prescriptions in our hospital during 2009- 2010. RESULTS： The use of anti-osteoporosis agent was based on calcium supplements and vitamine D in our hospital. Calcitonin accounted for the biggest proportion of consumption sum. Bisphosphonates and selective estrogen receptor modulator （SERM） were the conventional therapeutic medicine; single drug treatment took up about 76% of the total prescriptions. CONCLUSION： The drug use structure of anti-osteoporosis prescription is basically stable in accordance with the clinical therapy guideline, but the patients compliance research should be further strengthened.

关 键 词：抗骨质疏松症药 处方分析 用药依从性 

分 类 号：R969.3[医药卫生—药理学] R287[医药卫生—药学]